Format

Send to

Choose Destination
Rev Neurol. 2016 Aug 16;63(4):145-50.

[Response to treatment with interferon beta in patients with multiple sclerosis. Validation of the Rio Score].

[Article in Spanish; Abstract available in Spanish from the publisher]

Author information

1
Hospitals Vall d'Hebron, 08035 Barcelona, Espana.
2
Hospital Clinic de Barcelona, 08036 Barcelona, Espana.
3
Hospital Universitari Dr. Josep Trueta, 17007 Girona, Espana.
4
Hospital Universitari Son Espases, Palma de Mallorca, Espana.
5
Hospital Clinico San Carlos, 28040 Madrid, Espana.
6
Hospital Regional Universitario Carlos Haya, Malaga, Espana.
7
Hospital Universitario 12 de Octubre, Madrid, Espana.
8
Hospital Universitario Insular de Gran Canaria, 35016 Las Palmas de Gran Canaria, Espana.
9
UAM. Universidad Autonoma de Madrid. Hospital Universitario La Paz, 28046 Madrid, Espana.
10
Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Espana.
11
Hospital Universitario Virgen Macarena, 41003 Sevilla, Espana.
12
Hospital Donostia, 20014 San Sebastian, Espana.
13
Hospital Universitario Ramon y Cajal, 28034 Madrid, Espana.

Abstract

in English, Spanish

INTRODUCTION:

Different criteria have been proposed for the response to treatment with interferon beta, and the Rio Score is one of the most widely used. The aim of this study was to validate the usefulness of the Rio Score in an independent cohort.

PATIENTS AND METHODS:

A multi-centre, prospective, longitudinal study was conducted on patients with relapsing-remitting multiple sclerosis treated with interferon beta. The patients were classified according to the presence of attacks, active lesions (new in T2 or gadolinium enhancing lesions) in magnetic resonance imaging, a confirmed increase in disability or combinations of these variables (attacks, increase on the Expanded Disability Status Scale and active lesions) after one year's treatment. Regression analysis was used in order to identify the response-predicting variables after a three-year follow-up.

RESULTS:

The sample consisted of 249 patients with relapsing-remitting multiple sclerosis. The logistic model confirmed that the presence of two (odds ratio = 6.6; CI 95% = 2.7-16.1; p < 0.0001) or three (odds ratio = 8.5; CI 95% = 1.6-46; p < 0.01) positive variables during the first year of treatment were indicative of a significant risk of activity (attacks or progression) in the next two years.

CONCLUSIONS:

The usefulness of the Rio Score is confirmed, in an independent cohort, as a means of identifying patients with a higher risk of developing clinical activity or progression of disability during treatment with interferon beta.

PMID:
27439483
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Viguera Editores, S. L.
Loading ...
Support Center